Díaz LJ, Sardiñas PG, Menéndez CS, Macías AC

Language: Spanish
References: 29
Page:
PDF size: 51.72 Kb.

ABSTRACT

A pre-experimental study was conducted before then, in order to assess the effect of immunomodulator of ozone therapy in children with immunodeficiency defects of phagocytemediated immunity. The universe was made up by a total of 18 children with deficiencies in phagocytosis, assisted in the Immunology consultation from September 2009 until June 2010 that met the inclusion and exclusion criteria. Ozone was applied in doses by rectal insufflation stepped up a 40μg/mL concentration, for three months. The variables were assessed 1 month after treatment. It was determined if there are significant differences between determinations before and after of ozone therapy, through T of means comparison test for dependent samples, with a significance level α = 0. 05. There were significant increases in the absolute neutrophil count in 100% of cases and the Leukocyte Phagocytic function significantly improved in a 94% after receiving ozone therapy. The clinical state, qualitatively evaluated, was satisfactory in children treated with ozone and no adverse reactions were reported during treatment. It is suggested this therapeutic approach as immunostimulant therapeutic alternative in the phagocytic deficiency.

REFERENCES

1. Pancer Z, Cooper MD. The evolution of adaptive immunity. Ann Rev Immunol. 2006; 24: 497–518.

2. Abbas AK, Lichtman AH, Pober JS. Inmunología celular y molecular. 6ta ed. Madrid: McGraw- Hill-Interamericana de España; 2011.

3. Fisher A. Human primary immunodeficiency disease: a perspective. Nat Immunol. 2004; 5(1): 23-30.

4. Daniel P, Stites, Abba I, Terr T, Parslow G. Inmunología básica y clínica. 9na ed. México: ElManual Moderno; 1998.

5. Schonbein C. The discoverer of Ozone. Annual Report of the Board of Regents of the Smithsonian Institute. 2000; 1: 185-92.

6. Babior BM, Takeuchi C. Investigating antibody-catalyzed ozone generation by human neutrophils. Proc Nat Acad Sci U S A. 2003; 100(6): 3031-3034.

7. Bocci V, Aldinucci C, Borrelli E, Corradeshi F, Diodori A, Fanetti G, et al. Ozone in Medicine. Ozone Sci Engin. 2001; 23:207-17.

8. Bocci V. Biological and clinical effects of Ozone. Has Ozone therapy a future in medicine? Br J Biomed Sci. 2006; 56(4): 270-279.

9. Arencibia Jorge R, Leyva Rodríguez Y, Collymore Rodríguez A, Araújo Ruiz JA. Producción científica sobre aplicaciones terapéuticas del Ozono en el “web of science”. ACIMED [Internet]. 2006 [citado 3 Ene 2011]; 14(1): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1024-94352006000100007&lng=es&nrm=iso&tlng=es

10. MMenéndez S, González R, Ledea OE, Hernández F, León OS, Díaz M. Ozono: aspectos básicos y aplicaciones clínicas. 1ra ed. La Habana: CENIC; 2008.

11. Hoffman R. Hematology basic: principles y practice. 2nd ed. Edinburgh: Churhill Livingstone; 1995.

12. Ronald JH, Giclas PC. Diagnostic immunology laboratory manual. 1 ed. New York: Raven Press; 1991.

13. Balows AEH, Hasler WJ, Truant JP. Manual de Microbiología Clínica. 4ta ed. La Habana: Editorial Científico Técnica; 1985.

14. Reyes González S, Reyes González E. Terapéutica con Ozono y consentimiento informado [Internet]. 2002 [citado 3 Ene 2011] [aprox. 3 pantallas]. Disponible en: http://www.Institutobiologico.com/publicaciones/indexmed-journal/edition3.2002.

15. Bainton DF, Ulloa JL, Frrguhar MG. The development of neutrophilic polymorphonuclear leukocytes in human bone marrow. J Exp Med. 2007: 907-939.

16. Dale DC, Boxer L, Liles WC. The phagocytes: neutrophils and monocytes. Blood. 2004; 112 (4): 935–45. se consulta en: http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=18684880

17. Lanza F. Clinical manifestation of myeloperoxidase deficiency. J Mol Med. 1998; 76:676-81.

18. Cos Padrón Y, Torres Leyva I, Marsán Suárez V, Macías Abraham C. Defectos en la fagocitosis: aspectos clínicos, moleculares y terapéuticos. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2004 [citado 3 Ene 2011]; 20(1): [aprox. 8 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892004000100002&lng=es&nrm=iso&tlng=es

19. Wilson DR. Allergy. J Clin Immunol. 2006; 1(13):1025-34.

20. Porcellporcellini A, Dall'Aglio R, Ubaldi A. Effect of hypoxia and Ozone treatment on normal hemopoietic stem cells and clonogenic tumor cells. In vitro cleansing intended for autologous bone marrow transplantation. Hematol Cremona. 2004; 29: 6-8.

21. B Bocci V, Luzzi E, Corradeschi F, Paulesu L, Di Stefano A. Studies on the biological effects of Ozone 3: an attempt to define conditions for optimal induction of cytokines. Lymphok Cytok Res. 1993; 12(2): 121-126.

22. Paulesu L, Luzzi E, Bocci V. Studies on the biological effects of Ozone: induction of tumor necrosis factor on human leucocytes. Lymphok Cytok Res. 2006; 10:5.

23. Biosalud. La ozonoterapia [Internet]. 2009 [citado 21 Ene 2011] [aprox. 4 pantallas]. Disponible en: http://medicablogs.Diariomedico.com/institubiosalud/2009/04/15/la–medicinafuncional-2/respond

24. Bocci V, Paulesu L. Studies on the biological effects of Ozone 1. Induction of interferon gamma on human leucocytes. Haematologica. 2006; 75: 510-155.

25. L'ossigeno ozono terapia: una guida pratica [Internet]. 2009 [citado 21 Ene 2011] [aprox. 4 pantallas]. Disponible en: http://medicinapolispecistica.wordpress.com/2009/12/12usodelOzono-en-terapiamédica

26. Regeneración celular utilización celular del Ozono para uso medicinal [Internet]. 2007 [citado 21 Ene 2011] [aprox. 4 pantallas]. Disponible en: http://www.olx.cl

27. Riva Sanseverino E. Aspetti immunologici dell'ozonoterapia. Riv Italiana Omotossicol. 2009; 3:19-24.

28. Cardile V, Jiang X, Russo A, Casella F, Renis M, Bindoni M. Effects of Ozone on some biological activities of cells in vitro. Cell Biol Toxicol. 2005; 11: 11-21.

29. Bocci V, Luzzi E, Corradeschi F, Silvestri S. Studies of the biological effects of Ozone. Production of transforming growth factor B1 by human blood after Ozone treatment. J Biol Regulat Homeost Agent. 2000; 8: 108-112.